[Latest Research] Uveitis Market Will Generate Booming Growth Opportunities to 2024

The Uveitis Market is likely to grow immensely, i.e. reach US$ 40 Mn at a CAGR of 6.8%. Physical health apps are gaining popularity. They are inclusive of calorie trackers, step-counters, and exercise and nutrition-based apps. These apps are to be at the forefront with regards to capitalizing on those having chronic ailments like high blood pressure, heart diseases, or diabetes. This would be a significant arm of the healthcare industry.

In its recently published report titled "Uveitis Treatment Market: Industry Analysis and Forecast, 2016-2024," the company provides in-depth analysis of the market growth prospects for the eight-year assessment period, backing it up with historic and current market data.

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐭𝐡𝐞 𝐬𝐚𝐦𝐩𝐥𝐞 𝐜𝐨𝐩𝐲 𝐨𝐟 𝐫𝐞𝐩𝐨𝐫𝐭 -
https://www.persistencemarketresearch.com/samples/3596

𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐏𝐫𝐨𝐟𝐢𝐥𝐞𝐬:
• Allergan, Inc.,
• Bausch & Lomb Incorporated.
• Novartis AG (Alcon Laboratories Inc.)
• AbbVie Inc.
• Santen Pharmaceutical Co., Ltd
• Eyegate Pharmaceuticals, Inc.
• Alimera Sciences, Inc.
• pSivida Corp.
• Others
𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐅𝐨𝐫 𝐑𝐞𝐩𝐨𝐫𝐭 𝐂𝐮𝐬𝐭𝐨𝐦𝐢𝐳𝐚𝐭𝐢𝐨𝐧 - https://www.persistencemarketresearch.com/request-customization/3596

𝐏𝐞𝐫𝐬𝐢𝐬𝐭𝐞𝐧𝐜𝐞 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐢𝐝𝐞𝐧𝐭𝐢𝐟𝐢𝐞𝐝 𝐚 𝐟𝐞𝐰 𝐢𝐦𝐩𝐨𝐫𝐭𝐚𝐧𝐭 𝐝𝐫𝐢𝐯𝐞𝐫𝐬 𝐚𝐧𝐝 𝐭𝐫𝐞𝐧𝐝𝐬 𝐭𝐡𝐚𝐭 𝐰𝐢𝐥𝐥 𝐜𝐨𝐧𝐭𝐢𝐧𝐮𝐞 𝐭𝐨 𝐩𝐫𝐞𝐬𝐞𝐧𝐭 𝐚𝐭𝐭𝐫𝐚𝐜𝐭𝐢𝐯𝐞 𝐠𝐫𝐨𝐰𝐭𝐡 𝐨𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐢𝐞𝐬 𝐝𝐮𝐫𝐢𝐧𝐠 𝟐𝟎𝟏𝟔-𝟐𝟎𝟐𝟒.

While surge in autoimmune disorders is identified to primarily generate the demand for uveitis, the market has been witnessing strong emergence of immunosuppressive therapies to treat uveitis since the past few years, which is expected to create a new set of opportunities for leading players in near future.

"Some of the leading companies in the uveitis treatment marketplace have been investing in new, improved product launches since the past decade. While a significant number of uveitis drugs are already in the pipeline, increasing in-licensing approvals for new market entrants will boost the scope of treatment against uveitis, ultimately creating new lucrative opportunities," states Persistence Market Research.

• Increasing demand for generic drugs also prompt at an important trend in the global uveitis treatment market that will reportedly generate a range of opportunities for established as well as new pharma players.

• In addition to growing R&D activities in the field of eye disorders, rising optometric clinical practice will also provide an impetus to market growth.

• With surging uveitis prevalence, a host of biological drug development projects is anticipated to push the potential of the uveitis treatment market.

• Moreover, growing prevalence of TB associated with intermediate uveitis will continue to push the opportunities in intermediate uveitis segment.

• Another proliferating trend in uveitis treatment market includes increasing demand for local steroid implants, especially for non-infectious posterior uveitis.

• As corticosteroid mono-therapy is no more considered the first line treatment for uveitis, the market has been witnessing introduction of various modified corticosteroid medication and drug delivery methods since the recent past.

• Major players in the segment are working to add novel drugs to their product portfolio.

• R&D in topical agents segment will also benefit the market growth in near future.

𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧 𝐛𝐲 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐭𝐲𝐩𝐞:

• Corticosteroids
• Immunosuppressants
• Monoclonal antibodies
• Cycloplegic agents
• Antibodies
• Antivirals
• Antifungals
• Analgesics

Corticosteroids will remain the largest segment, followed by antibiotics and monoclonal antibodies. While corticosteroids segment is foreseen to account for a dominant market share of over 21% in 2024, antibiotics segment is expected to witness the fastest growth at a CAGR of 8% - reaching beyond US$ 146 Mn over 2016-2024. Monoclonal antibodies segment will also exhibit healthy growth at a CAGR of 7%, reaching revenues worth US$ 142.7 Mn by the end of 2024.

𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧 𝐛𝐲 𝐝𝐢𝐬𝐞𝐚𝐬𝐞 𝐭𝐲𝐩𝐞:
• Anterior uveitis
• Posterior uveitis
• Intermediate uveitis
• Panuveitis

Anterior uveitis segment will continue to dominate. Through 2024, this segment will capture around 60% value share, representing a value of over US$ 500 Mn. Posterior uveitis is also estimated for a considerable market value share of over 23% in 2024. Attributed to increased prevalence of TB in intermediate uveitis, the intermediate uveitis will possibly be the second fastest growing segment over the forecast period.

𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧 𝐛𝐲 𝐜𝐚𝐮𝐬𝐞:
• Infectious
• Non-infectious

On the basis of cause, infectious uveitis will remain the larger segment with over 87% share by 2024 end but non-infectious uveitis is predicted to witness a higher CAGR of 7.4% during the eight-year period.

𝐅𝐨𝐫 𝐈𝐧-𝐃𝐞𝐩𝐭𝐡 𝐂𝐨𝐦𝐩𝐞𝐭𝐢𝐭𝐢𝐯𝐞 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬,𝐁𝐮𝐲 𝐍𝐨𝐰 -https://www.persistencemarketresearch.com/checkout/3596

𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧 𝐛𝐲 𝐫𝐞𝐠𝐢𝐨𝐧:

The report provides regional analysis that examines the global market classifying it into five key regions.

• North America
• Latin America
• Europe
• Asia Pacific (APAC)
• Middle East and Africa (MEA)

𝐀𝐛𝐨𝐮𝐭 𝐏𝐞𝐫𝐬𝐢𝐬𝐭𝐞𝐧𝐜𝐞 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡:

Business intelligence is the foundation of every business model employed by Persistence Market Research. Multi-dimensional sources are being put to work, which include big data, customer experience analytics, and real-time data collection. Thus, working on "micros" by Persistence Market Research helps companies overcome their "macro" business challenges.

Persistence Market Research is always way ahead of its time. In other words, it tables market solutions by stepping into the companies'/clients' shoes much before they themselves have a sneak pick into the market. The pro-active approach followed by experts at Persistence Market Research helps companies/clients lay their hands on techno-commercial insights beforehand, so that the subsequent course of action could be simplified on their part.

𝐂𝐨𝐧𝐭𝐚𝐜𝐭

Rajendra Singh
Persistence Market Research
U.S. Sales Office:
305 Broadway, 7th Floor
New York City, NY 10007
+1-646-568-7751
United States
USA - Canada Toll-Free: 800-961-0353
Email: sales@persistencemarketresearch.com

This release was published on openPR.